Castle Biosciences: TissueCypher Ramp Validates Growth Story, But Q2 Peak And Margin Compression Demand Caution — Upgrade To Buy

Castle Biosciences delivered the kind of quarter that separates turnaround stories from permanent ones — and the market knows it. Revenue of $103.5 million smashed the consensus estimate of approximately $86–88 million by roughly 18–20%. The adjusted loss of $0.07 per share was far better than the $0.40–$0.44 loss analysts expected. Management raised full-year revenue guidance for the second time in six months to $365–375 million from $345–$355 million, and now expects positive adjusted EBITDA — earnings before interest, taxes, depreciation, and amortization, a rough proxy for operating cash generation — for the remainder of 2026 and into 2027.

The stock has responded accordingly, up approximately 35% over the past 20 days. It still trades well below its 52-week high of $44.28 and down 17.7% year-to-date. Analysts raised their price target from $52 to $57 in the days following the report.

The question is whether the TissueCypher volume surge that powered this quarter is the start of a new growth phase or a one-time collection spike. The evidence points toward the former, but the margin compression and the fact that management's own guidance implies H2 deceleration from the Q2 peak mean this is not a clear-run upgrade. I am upgrading Castle Biosciences to Buy, but with the caveat that Q3 earnings will separate conviction from speculation.

What Changed

The driver is unambiguous. TissueCypher, Castle's test that predicts progression risk for patients with Barrett's esophagus — a precursor condition to esophageal cancer — generated 14,988 test reports in Q2, up 63% year-over-year from 9,170. It has now overtaken the company's legacy DecisionDx-Melanoma test (10,280 reports, just 3% growth) as the volume leader. This marks a meaningful strategic pivot from dermatology to gastroenterology.

Core revenue growth excluding the legacy DecisionDx-SCC product and the discontinued IDgenetix franchise was 40% year-over-year. Management says TissueCypher penetration stands at 10–12% of the addressable patient base, with a path to mid-teens this year. At that penetration rate, there is substantial runway. The company also updated its full-year TissueCypher volume growth outlook to 50–52%, up from its prior guidance.

The earnings beat itself was dramatic. Castle delivered an adjusted EPS loss of just $0.07 versus a consensus loss of $0.40–$0.44 — an 82% positive surprise on the earnings line. That is the kind of beat that resets expectations and forces analysts to rethink their models.

The Margin Problem

Here is where the story gets harder. Gross margin compressed to 74.9% on a GAAP basis, down from 77.3% a year ago. The adjusted gross margin fell to 76.3% from 79.5%. Management attributed the compression to higher costs from volume growth, laboratory supply expenses, and a product mix shift toward TissueCypher, which carries a lower margin than Castle's older tests. Full-year 2026 adjusted gross margin guidance is in the low-to-mid 70% range.

Operating expenses totaled $106.6 million in Q2, up from $90.4 million a year ago. Sales and marketing grew 17% to $40.9 million. General and administrative was $25.2 million, up 10%. R&D was $14.5 million, up 13%. Stock-based compensation alone was $11.6 million, representing 11.2% of revenue.

The result: a GAAP net loss of $2.1 million, compared to net income of $4.5 million a year ago. The company is spending aggressively to fund sales force expansion, clinical evidence generation, and laboratory capacity. That is the right call for a company in a volume ramp, but the expense growth outpaces revenue growth in absolute dollar terms, and the margin profile is trending in the wrong direction.

The Sequential Deceleration Signal

The raised full-year guidance tells you something the headline does not. With first-half revenue at approximately $187.2 million ($83.7 million in Q1 plus $103.5 million in Q2), the midpoint of the new $365–375 million guidance implies second-half revenue of approximately $183–188 million, or roughly $91–94 million per quarter. That is a sequential decline from Q2's $103.5 million.

Management advised investors to look at multi-quarter trends rather than sequential performance due to seasonality. The ASP improvement in Q2, driven by better payer experience and accrual adjustments, was explicitly flagged as a one-time step-up that is not expected to repeat. Wall Street's consensus for the next quarter sits at $91.5 million in revenue and a $0.33 loss per share — both a step down from Q2's actuals.

This is not necessarily a red flag, but it is worth noting. Q2 benefited from ASP recovery and potentially accelerated payer collections. The test of whether TissueCypher's 63% volume surge is structural comes in Q3, when ASP normalizes and the higher-volume base compounds.

Valuation: Still Cheap Relative To Growth

At a market cap of approximately $979 million and an enterprise value of $722 million (the company holds $266.8 million in net cash against $91 million in debt), Castle trades at 2.74 times trailing sales on a price basis and 2.02 times EV/sales. Those multiples are a fraction of what the market pays for comparable molecular diagnostics companies. CareDx trades at 5.27 times sales. Veracyte trades at 6.76 times sales. Grail, despite its own losses, commands 18.78 times sales.

The PEG ratio (price-to-earnings-growth) sits at 0.47, meaning the stock's multiple is less than half of what you would expect for its growth rate if it were priced in line with conventional growth-stock math. Whether that holds depends on whether Castle can convert the TissueCypher volume surge into durable operating leverage.

The balance sheet is strong. $266.8 million in cash and marketable securities gives the company roughly three years of runway at current burn rates. There is no near-term dilution risk.

The Catalyst Clock

Three near-term events matter:

• Q3 earnings: The first test of whether TissueCypher volume growth sustains at the 50%+ pace without the one-time ASP boost. Consensus expects $91.5 million in revenue and a $0.33 loss per share. A beat here, combined with maintained guidance, would validate the TissueCypher thesis.
• DecisionDx-SCC Medicare coverage: Draft coverage decisions are expected in the second half of 2026. A positive outcome would unlock the SCC franchise from its current 16% volume decline. Final coverage could follow in mid-2027, with the Novitas and MolDX reconsideration modeled for approximately 15 months.
• AdvanceAD-Tx: The atopic dermatitis test received a unanimous 21–0 Medicare crosswalk recommendation at a reimbursement rate of $36.75 per test. With over 1,000 orders in Q2 and a full commercial launch expected in 2027, this is an optionality play, not a near-term revenue driver.

Risks

• DecisionDx-Melanoma growth has stalled at 3% year-over-year. The legacy franchise is losing share, and management acknowledges the sales force is stretched across three products simultaneously.
• Gross margin compression is real. The shift to lower-margin TissueCypher, combined with higher operating spend, means Castle is not yet generating the operating leverage investors typically demand from a profitable diagnostics company.
• DecisionDx-SCC reimbursement risk remains unresolved, with no guarantee of a favorable LCD reconsideration outcome.
• The sequential deceleration implied by the raised full-year guidance is a headwind for momentum investors who want to see accelerating quarterly prints.

Investor Takeaway

Castle Biosciences is priced as if TissueCypher is a promising experiment rather than the growth engine it has become. At 2.0 times EV/sales, the stock sits well below peers that are either profitable or trading at richer growth multiples. The TissueCypher ramp is real, the addressable market is still largely untapped, and the company has raised guidance twice in six months without burning through its cash pile.

The upgrade to Buy reflects the gap between the current multiple and the evidence of accelerating volume growth. But the risk/reward is not a slam dunk. Margin compression, the Q2 sequential peak, and the slow bleed of the legacy melanoma franchise mean investors need to watch Q3 carefully.

If Castle meets or exceeds the $91.5 million consensus and maintains its guidance trajectory, the valuation gap with peers becomes harder to ignore. If volumes decelerate or margins compress further, the upgrade case narrows to a Hold. The catalyst clock is set. Q3 earnings will tell the story.